Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Volitionrx Ltd filings on SEC EDGAR ↗
VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.
VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.
Term
Q3 2026
“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”
Cameron Reynolds, President and Group Chief Executive Officer